US EditionAI Tool Outperforms Existing Methods in Diagnosing Cardiac Amyloidosis
UNITED STATES, JUL 10 – The FDA-cleared AI model detects cardiac amyloidosis with 85% accuracy, aiding earlier diagnosis to improve survival through timely treatment, researchers said.
- In July 2025, researchers reported in the European Heart Journal on an AI algorithm designed to identify cardiac amyloidosis by analyzing echocardiogram videos.
- The AI model was developed by Mayo Clinic and Ultromics, Ltd. due to challenges in diagnosing cardiac amyloidosis, which is often underrecognized and hard to distinguish.
- The AI uses a neural network trained on 2,612 transthoracic echo clips to differentiate amyloidosis from similar heart conditions and integrates easily into clinical practice.
- The AI achieved 85% sensitivity, 93% specificity, and an AUROC of 0.93, outperforming traditional risk scores, and was FDA-cleared and validated across 18 global sites.
- Experts said the AI enables earlier diagnosis and treatment of cardiac amyloidosis, potentially improving patient outcomes and expanding use in routine cardiac care.
11 Articles
11 Articles
Clinically meaningful interpretability of an AI model for ECG classification
Despite the high accuracy of AI-based automated analysis of 12-lead ECG images for classification of cardiac conditions, clinical integration of such tools is hindered by limited interpretability of model recommendations. We aim to demonstrate the feasibility of a generic, clinical resource interpretability tool for AI models analyzing digitized 12-lead ECG images. To this end, we utilized the sensitivity of the Jacobian matrix to compute the gr…
AI accurately diagnosed cardiac amyloidosis on echocardiography
A new AI model accurately detected cardiac amyloidosis from echocardiograms with higher accuracy vs. other amyloidosis risk scores, according to research published in the European Heart Journal.“Cardiac amyloidosis is underrecognized and probably accounts for 15% of cases of HF with preserved ejection fraction. HFpEF accounts for about half of HF cases, so it is pretty substantial,”
News Medical
MSNAI tool outperforms existing methods in diagnosing cardiac amyloidosis
In a new study published in the European Heart Journal, researchers reported the successful development and validation of a medical artificial intelligence (AI) model that screens for cardiac amyloidosis, a progressive and irreversible type of heart disease.
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
